ArticleDiscover oncology2025
The effects of genetically determined plasma methyltransferases on digestive system cancers: a comprehensive bidirectional two-sample Mendelian randomization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe causal relationship between plasma methyltransferase protein concentrations and the onset of digestive system cancers remains unclear. This study employed a Mendelian randomization (MR) analysis to explore potential causal relationships.
methodsA bidirectional two-sample MR analysis was conducted to systematically investigate causal associations. Data from the FinnGen Biobank and the European Bioinformatics Institute (EBI) were used for verification. This analysis focused on 14 types of methyltransferases and 5 types of digestive system cancers.
resultsThe analysis identified specific methyltransferases associated with increased risks for certain digestive system malignancies. Notably, dual verification confirmed that HEMK2 is associated with an increased risk of colorectal cancer [Odds Ratio (OR) = 1.28; 95% CI: 1.06-1.55 for FinnGen; OR = 1.18; 95% CI: 1.07-1.29 for EBI] and liver cancer (OR = 2.31; 95% CI: 1.29-4.14 for FinnGen; OR = 1.38; 95% CI: 1.08-1.76 for EBI). NTMT1 was also associated with colorectal cancer (OR = 1.16; 95% CI: 1.03-1.30 for FinnGen; OR = 1.10; 95% CI: 1.04-1.17 for EBI) and liver cancer (OR = 1.59; 95% CI: 1.11-2.27 for FinnGen; OR = 1.21;95%CI: 1.04-1.40 for EBI). We also found that some methyltransferases exhibit either harmful or protective effects in digestive system cancers; however, these findings have not been validated by another independent database. Therefore, the interpretation of these results requires caution.
conclusionsThis study reveals that certain methyltransferases are associated with an increased risk of some digestive system cancers. HEMK2 and NTMT1 emerged as candidate genetically predicted biomarkers, meriting further research to elucidate their mechanistic functions and potential clinical applicability. Furthermore, as all genetic information in this study originates from European cohorts, the conclusions are primarily relevant to this population and necessitate validation in diverse ethnic groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.